|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017431,
umls-concept:C0019189,
umls-concept:C0026882,
umls-concept:C0030705,
umls-concept:C0035668,
umls-concept:C0087111,
umls-concept:C0220847,
umls-concept:C0229671,
umls-concept:C0376705,
umls-concept:C0521026,
umls-concept:C1274040
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-13
|
|
pubmed:abstractText |
We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). The first RI (RI-1st; the viral load at week 1 divided by the viral load at 24 h) and the second RI (RI-2nd; the viral load at week 2 divided by the viral load at 24 h) were calculated. The subject patients were divided into 3 groups based on RI-1st and RI-2nd: an RI-A group (RI-1st < or = 1.0), an RI-B group (RI-1st >1.0 and RI-2nd <0.7) and an RI-C group (RI-1st >1.0 and RI-2nd > or = 0.7). The SVR rate was 71.4% (10/14) in the RI-A group, 46.2% (6/13) in the RI-B group and 20.0% (3/15) in the RI-C group (p = 0.005 between the RI-A group and the RI-C group). In IRRDR > or = 6 and IRRDR < or = 5 the SVR rate was 81.3% (13/16) and 23.1% (6/26) (p = 0.0002), respectively. By combining RI and IRRDR as a predicting factor, the SVR rate was 87.5% (7/8) in the RI-A group (> or = 6 mutations in the IRRDR) and 7.7% (1/13) in the RI-C group (< or = 5 IRRDR mutations) (p = 0.0003).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0100
|
|
pubmed:author |
pubmed-author:El-ShamyAhmedA,
pubmed-author:HayashiYoshitakeY,
pubmed-author:HottaHakH,
pubmed-author:ImotoSusumuS,
pubmed-author:KimKe IhKI,
pubmed-author:KimSoo RyangSR,
pubmed-author:KudoMasatoshiM,
pubmed-author:MitaKeijiK,
pubmed-author:SasaseNorikoN,
pubmed-author:ShojiIkuoI,
pubmed-author:TaniguchiMiyukiM
|
|
pubmed:copyrightInfo |
Copyright 2010 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
49-54
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20068341-Aged,
pubmed-meshheading:20068341-Antiviral Agents,
pubmed-meshheading:20068341-Drug Resistance, Viral,
pubmed-meshheading:20068341-Drug Therapy, Combination,
pubmed-meshheading:20068341-Female,
pubmed-meshheading:20068341-Genotype,
pubmed-meshheading:20068341-Hepacivirus,
pubmed-meshheading:20068341-Hepatitis C, Chronic,
pubmed-meshheading:20068341-Humans,
pubmed-meshheading:20068341-Interferon-alpha,
pubmed-meshheading:20068341-Male,
pubmed-meshheading:20068341-Middle Aged,
pubmed-meshheading:20068341-Mutation, Missense,
pubmed-meshheading:20068341-Polyethylene Glycols,
pubmed-meshheading:20068341-RNA, Viral,
pubmed-meshheading:20068341-Recombinant Proteins,
pubmed-meshheading:20068341-Ribavirin,
pubmed-meshheading:20068341-Serum,
pubmed-meshheading:20068341-Treatment Outcome,
pubmed-meshheading:20068341-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
|
|
pubmed:affiliation |
Department of Pharmacy, Kobe Asahi Hospital, Kobe, Japan.
|
|
pubmed:publicationType |
Journal Article
|
